uniQure N.V. (QURE) stock
Close on Nov 13, 2026Market cap $1.65BP/E –Yield –
uniQure N.V. grew revenue 28.0% to $20.17M over the twelve months to Sep 30, 2026. Free cash flow was -$192.96M. At the latest close the market valued the company at $1.65B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.65B
- P/E ratio
- –
- Price to sales
- 81.90
- Price to book
- 5.61
- Dividend yield
- –
- Free cash flow yield
- -11.68%
Fundamentals
- Revenue
- $20.17M
- Net income
- -$232.90M
- EPS, diluted
- -$3.54
- Free cash flow
- -$192.96M
- Book value per share
- $4.22
- Diluted shares
- 70M
Trading
- Next earnings
- Mar 1, 2027 (estimated, before the open)
- Previous close
- $24.63
- Open
- $24.50
- Day's range
- $23.34 – $24.50
- Volume
- 1,394,513
- Average volume (20 days)
- 1,970,411
- Beta (5 years)
- 1.67
- 52-week range
- $8.73 – $51.72
- RSI (14 days)
- 45.7
- Volatility (1 year)
- 132.0%
- Relative volume
- 0.71×
- WACC
- 13.4%
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | QURE | S&P 500 | Difference | QURE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +11.9% | -3.0% | +14.9 pts | ||
| 3 months | -49.4% | -2.8% | −46.6 pts | ||
| Year to date | -0.5% | +11.5% | −12.0 pts | ||
| 1 year | -21.5% | +13.5% | −35.0 pts | ||
| 3 years | +296.8% | +77.7% | +219.1 pts | +58.3% | +21.1% |
| 5 years | -25.5% | +72.6% | −98.1 pts | -5.7% | +11.5% |
| 10 years | +192.5% | +308.2% | −115.7 pts | +11.3% | +15.1% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases uniQure filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- Results
About uniQure
Pharmaceutical Preparations
uniQure is a biotechnology company that develops genomic medicines and adeno-associated virus-based gene therapies for individuals living with severe genetic and debilitating illnesses. Its pipeline of investigational clinical treatments targets central nervous system and metabolic disorders, including Huntington’s disease, refractory mesial temporal lobe epilepsy, Fabry disease, and amyotrophic lateral sclerosis. The company also developed etranacogene dezaparvovec for hemophilia B, which is commercialized globally by partner CSL Behring under the brand name HEMGENIX.
Company profile, executives and historyuniQure stock: common questions
What is uniQure's stock price?
QURE closed at $23.81 on Nov 13, 2026, down 3.33% on the day. Over the past 52 weeks it traded between $8.73 and $51.72.
What is uniQure's market cap?
uniQure was worth $1.65B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is QURE's P/E ratio?
uniQure lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.54), so it has no meaningful P/E ratio.
How much revenue does uniQure make?
uniQure reported revenue of $20.17M for the twelve months to Sep 30, 2026, up 28.0% from a year earlier.
Does uniQure pay a dividend?
No. uniQure has not paid a cash dividend over the last twelve months.
When does uniQure report earnings next?
uniQure is expected to report Q4 FY2026 results on Mar 1, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has QURE stock performed over the past year?
Including dividends, QURE returned -21.5% over the past year, against +13.5% for the S&P 500.
How many QURE shares are sold short?
9M shares were sold short at the latest FINRA report, 12.53% of the float, or 6.4 days of average trading volume.
Who are uniQure's competitors?
Companies most similar to uniQure by business, industry and size include STOK, PRQR, NAMS, WVE, CAPR.
See a number that looks wrong?